Brusatol sensitizes endometrial hyperplasia and cancer to progestin by suppressing NRF2-TET1-AKR1C1-mediated progestin metabolism

• Published in: Laboratory investigation 2022-12, Vol.102 (12), p.1335-1345
• Main Authors: Hu, Meiyan, Sun, Di, Yu, Jing, Fu, Yue, Qin, Zuoshu, Huang, Baozhu, Zhang, Qiuju, Chen, Xiong, Wei, Youheng, Zhu, Huiting, Wang, Yue, Feng, Youji, Zheng, Wenxin, Liao, Hong, Li, Jingjie, Wu, Sufang, Zhang, Zhenbo
• Format: Article
• Language: English
• Subjects: 13/1; 13/51; 14; 38; 38/22; 38/77; 42; 42/109; 631/154/155; 631/67/1059/2326; 82/58; 96; Animal models; Animals; Barriers; Biomarkers; Cancer; Catabolism; DNA-Binding Proteins; Endometrial cancer; Endometrial Hyperplasia - drug therapy; Endometrial Hyperplasia - genetics; Endometrial Neoplasms - drug therapy; Endometrial Neoplasms - genetics; Endometrial Neoplasms - metabolism; Endometrium; Female; Fertility; Humans; Hyperplasia; Laboratory Medicine; Medicine; Medicine & Public Health; Metabolism; Mice; Mixed Function Oxygenases - metabolism; NF-E2-Related Factor 2 - metabolism; Organoids; Pathology; Progesterone; Progestin; Progestins - pharmacology; Proto-Oncogene Proteins - metabolism; Xenografts; Xenotransplantation
• ISSN: 0023-6837; 1530-0307
• DOI: 10.1038/s41374-022-00816-5

Progestin resistance is the main obstacle for the conservative therapy to maintain fertility in women with endometrial cancer. Brusatol was identified as an inhibitor of the NRF2 pathway; however, its impact on progestin resistance and the underlying mechanism remains unclear. Here, we found that brusatol sensitized endometrial cancer to progestin by suppressing NRF2-TET1-AKR1C1-mediated progestin metabolism. Brusatol transcriptionally suppressed AKR1C1 via modifying the hydroxymethylation status in its promoter region through TET1 inhibition. Suppression of AKR1C1 by brusatol resulted in decreased progesterone catabolism and maintained potent progesterone to inhibit endometrial cancer growth. This inhibition pattern has also been found in the established xenograft mouse and organoid models. Aberrant overexpression of AKR1C1 was found in paired endometrial hyperplasia and cancer samples from the same individuals with progestin resistance, whereas attenuated or loss of AKR1C1 was observed in post-treatment samples with well progestin response as compared with paired pre-treatment tissues. Our findings suggest that AKR1C1 expression pattern may serve as an important biomarker of progestin resistance in endometrial cancer. For precancerous/endometrial cancer patients with fertility maintain desire, progestin resistance is the main obstacle of conservative therapy. The authors found that brusatol, as a natural compound, suppresses progestin metabolism through regulating the NRF2-TET1-AKR1C1 pathway to sensitize precancerous/endometrial cancers to progestin and relieve progestin resistance. This study indicates that progestin combined with brusatol may enhance the treatment effects and that AKR1C1 expression patterns may serve as an important biomarker of progestin resistance in endometrial cancer.